Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Advertisement

Close

AACR Journals
For Authors
About Us
Article Collections
Alerts
News
Cancer Hallmarks
Webinars

header search

search input Search input auto suggest

Search

Advanced Search

Menu

About
Articles
First Disclosures
For Authors
Alerts
News
Cancer Hallmarks
Webinars

Skip Nav Destination

Current Issue

Volume 23,

Issue 4

1 April 2024

View This Issue

About the Journal

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.. Read More About the Journal

Editor-in-Chief

Beverly A Teicher

View Full Editorial Board

Impact Factor

5.7

SUBMIT TO JOURNAL

Featured Articles

First Disclosure

Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth

Kyle Begovich, et al.

First Disclosure

XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Ekta Patel, et al.

Biomarkers for Antibody–Drug Conjugates in Solid Tumors

Jalissa Katrini, et al.

Trending - Altmetric

The article titled, The Role of Autophagy in Cancer: Therapeutic Implications, has an Alt Metric Attention Score of 54.662. Click to see more of this article's metrics.

Read the article titled, The Role of Autophagy in Cancer: Therapeutic Implications

Last mentioned on Monday April 15 2024

The article titled, Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer, has an Alt Metric Attention Score of 11.15. Click to see more of this article's metrics.

Read the article titled, Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer

Last mentioned on Monday April 15 2024

Latest
Most Read
Most Cited

Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus

Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer

A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors

Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas

The Twitter live feed is not currently active.

Keep up to date with Molecular Cancer Therapeutics

Follow @MCT_AACR

Issues
Online First
News

Twitter

Online ISSN 1538-8514
Print ISSN 1535-7163

AACR Journals

Blood Cancer Discovery
Cancer Discovery
Cancer Epidemiology, Biomarkers & Prevention
Cancer Immunology Research
Cancer Prevention Research
Cancer Research
Cancer Research Communications
Clinical Cancer Research
Molecular Cancer Research
Molecular Cancer Therapeutics

Info for Advertisers
Information for Institutions/Librarians
RSS Feeds
Privacy Policy

Twitter
LinkedIn
Facebook
Youtube

Copyright © 2023 by the American Association for Cancer Research.

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.

Accept